AIMS: Medullary carcinomas (MCs) represent a rare breast cancer subtype associated with a rather favourable prognosis compared with invasive ductal carcinomas (IDCs). Due to histopathological overlap, MCs are frequently misclassified as high-grade IDCs, potentially leading to overtreatment of MCs. Our aim was to establish novel diagnostic markers distinguishing MCs from hormone receptor-negative high-grade IDCs. METHODS AND RESULTS: Sixty-one MCs and 133 hormone receptor-negative IDCs were analysed in a comparative immunohistochemical study. Applied markers included a comprehensive panel of cytokeratins (CKs), vimentin, smooth muscle actin (SMA), p63, p53, cell adhesion molecules [N-CAM (CD56), syndecan-1 (CD138), E-cadherin and P-cadherin] and development associated transcription factors (AP-2 alpha, AP-2 gamma). A significantly higher proportion of IDCs displayed increased expression of CK7, AP-2 alpha and HER2 in contrast to MCs (CK7: 91% of IDCs versus 77% of MCs; AP-2 alpha: 77% versus 57%; and HER2: 26% versus 7%, each P < 0.01). Vice versa, MCs were slightly more frequently positive for SMA and vimentin (P > 0.05). CONCLUSIONS: Hormone receptor-negative high-grade IDCs are significantly associated with luminal differentiation, Her2 and AP-2 alpha overexpression, whereas MCs tend to display myoepithelial features. Markers analysed in this study are of diagnostic value regarding the differential diagnosis of MCs.
AIMS: Medullary carcinomas (MCs) represent a rare breast cancer subtype associated with a rather favourable prognosis compared with invasive ductal carcinomas (IDCs). Due to histopathological overlap, MCs are frequently misclassified as high-grade IDCs, potentially leading to overtreatment of MCs. Our aim was to establish novel diagnostic markers distinguishing MCs from hormone receptor-negative high-grade IDCs. METHODS AND RESULTS: Sixty-one MCs and 133 hormone receptor-negative IDCs were analysed in a comparative immunohistochemical study. Applied markers included a comprehensive panel of cytokeratins (CKs), vimentin, smooth muscle actin (SMA), p63, p53, cell adhesion molecules [N-CAM (CD56), syndecan-1 (CD138), E-cadherin and P-cadherin] and development associated transcription factors (AP-2 alpha, AP-2 gamma). A significantly higher proportion of IDCs displayed increased expression of CK7, AP-2 alpha and HER2 in contrast to MCs (CK7: 91% of IDCs versus 77% of MCs; AP-2 alpha: 77% versus 57%; and HER2: 26% versus 7%, each P < 0.01). Vice versa, MCs were slightly more frequently positive for SMA and vimentin (P > 0.05). CONCLUSIONS:Hormone receptor-negative high-grade IDCs are significantly associated with luminal differentiation, Her2 and AP-2 alpha overexpression, whereas MCs tend to display myoepithelial features. Markers analysed in this study are of diagnostic value regarding the differential diagnosis of MCs.
Authors: J Huober; S Gelber; A Goldhirsch; A S Coates; G Viale; C Öhlschlegel; K N Price; R D Gelber; M M Regan; B Thürlimann Journal: Ann Oncol Date: 2012-06-14 Impact factor: 32.976
Authors: Inhye Park; Jiyoung Kim; Minkuk Kim; Soo Youn Bae; Se Kyung Lee; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam Journal: J Breast Cancer Date: 2013-12-31 Impact factor: 3.588
Authors: Jose Villacorta Hidalgo; Peter Bronsert; Marzenna Orlowska-Volk; Liliana B Díaz; Elmar Stickeler; Martin Werner; Annette Schmitt-Graeff; Gian Kayser; Miroslav Malkovsky; Paul Fisch Journal: Front Immunol Date: 2014-12-10 Impact factor: 7.561
Authors: Michał P Budzik; Maciej T Sobieraj; Maria Sobol; Janusz Patera; Aleksandra Czerw; Andrzej Deptała; Anna M Badowska-Kozakiewicz Journal: Arch Med Sci Date: 2019-07-17 Impact factor: 3.318
Authors: P Lebok; V Kopperschmidt; M Kluth; C Hube-Magg; C Özden; Taskin B; K Hussein; A Mittenzwei; A Lebeau; I Witzel; L Wölber; S Mahner; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; Ronald Simon; Guido Sauter; L Terracciano; R Krech; A von d Assen; V Müller; E Burandt Journal: BMC Cancer Date: 2015-12-16 Impact factor: 4.430